

Madrid, June 25, 2026

LABIANA HEALTH, S.A. (hereinafter, the “Company”), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, and in accordance with Article 227 of Law 6/2023 of March 17 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, regarding information to be provided by companies listed on that segment, hereby announces the following:

OTHER RELEVANT INFORMATION

Resolutions of the General Shareholders’ Meeting

At the Company’s Ordinary General Shareholders’ Meeting held on June 19, 2026, at 11:00 a.m., on first call, in Madrid, at the Company’s registered office located at Av. Europa, 34D, 28023 Pozuelo de Alarcón (Madrid), with shareholders present or represented shareholders representing 78.4% of the Company’s share capital, all of the proposed resolutions submitted to the General Meeting for approval were unanimously approved.

In compliance with the provisions of Circular 3/2020 of the BME MTF Equity, it is hereby expressly stated that the information disclosed herein has been prepared under the sole responsibility of the Company and its directors.

We remain at your disposal for any clarifications you may require.

Sincerely,

Mr. Manuel Ramos Ortega,
Chief Executive Officer,
LABIANA HEALTH, S.A.

LABIANA HEALTH, S.A.

Resolutions Approved by the 2026 Annual General Meeting of Shareholders

The following is a transcript of the resolutions approved by the Ordinary General Shareholders' Meeting of LABIANA HEALTH, S.A., held on June 19, 2026, on first call, along with the voting results.

Item 1: Review and approval of the Company's Individual Financial Statements (balance sheet, income statement, statement of changes in equity, cash flow statement, and individual management report) and the individual management report for the fiscal year ended December 31, 2025, duly audited

To approve the Individual Annual Financial Statements (balance sheet, income statement, statement of changes in equity, cash flow statement, and individual management report), as well as the individual management report of LABIANA HEALTH, S.A. (the "Company"), for the fiscal year ended December 31, 2025, prepared by the Company's Board of Directors on March 25, 2026, following a report from the Audit Committee, and which have been duly audited by the Company's auditor.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 2.—Review and approval of the Consolidated Financial Statements (consolidated balance sheet, income statement, statement of changes in equity, cash flow statement, and notes to the financial statements) and the consolidated management report of the Company and its subsidiaries, for the fiscal year ended December 31, 2025, duly audited

To approve the Consolidated Annual Financial Statements (consolidated balance sheet, income statement, statement of changes in equity, cash flow statement, and management report), as well as the consolidated management report (which includes the Consolidated Non-Financial Information Statement in a separate report) of the Company and its subsidiaries, prepared by the Company's Board of Directors on March 25, 2026, following a report from the Audit Committee, and which have been duly audited by the Company's auditor. Likewise, to approve the consolidated net income in the amount of 2,554,096.16 euros, with the net income attributable to the parent company amounting to 2,569,177.05 euros.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 3.—Review and approval of the Consolidated Non-Financial Information Statement of the Company and its subsidiaries for the fiscal year ended December 31, 2025, duly audited

In compliance with the provisions of Article 262 of the Capital Companies Act and Article 49 of the Commercial Code, to approve the Consolidated Non-Financial Information Statement, which forms an integral part of the consolidated management report of the Company and its subsidiaries for the fiscal year ended December 31, 2025, as prepared by the Company's Board of Directors on March 25, 2026, and duly verified by an independent verification service provider.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 4.—Review and approval of the proposal for the appropriation of net income for the fiscal year ended December 31, 2025.

Given the Company's net loss of –1,748,632.18 euros, the proposal for the appropriation of the Company's net income for the fiscal year ended December 31, 2025, is hereby approved and allocated to the "Net Losses from Prior Years" account.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 5. Approval of the management and conduct of the Board of Directors during the fiscal year ended December 31, 2025

To approve the management and conduct of the Company's Board of Directors during the fiscal year ended December 31, 2025.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 6. Re-election of the auditor for the Company and its Consolidated Group for fiscal year 2026.

To re-elect, upon the recommendation of the Audit Committee, as the auditor of the Company and the Company's Consolidated Group for a term of one (1) year, that is, to conduct the audit of the annual financial statements for the 2026 fiscal year, the firm AUREN AUDITORES SP SLP, with its registered office at Avenida General Perón, 38, 28020 Madrid, Tax ID No. B87352357, registered in the Madrid Commercial Registry in Volume 33,829,

Folio 89, Page

M-608,799, and registered in the Official Register of Auditors (ROAC) of the Institute of Accounting and Auditing of the Ministry of Economy and Competitiveness under number S2347.

AUREN AUDITORES SP SLP will accept the appointment by means of a separate document to be attached to the certification of the Minutes for registration in the Commercial Registry.

This appointment is for a term of one year beginning on January 1, 2026—the date on which the current fiscal year began—and will include the audit for the fiscal year ending December 31, 2026.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 7.—Delegation to the Board of Directors of the authority to increase the share capital pursuant to Article 297.1.b) of the Capital Companies Act. Delegation to exclude the right of first refusal in accordance with the provisions of Article 506 of the Capital Companies Act

In accordance with the provisions of Article 297.1.b) of the Capital Companies Act, the Board of Directors of the Company is hereby delegated the authority to increase, on one or more occasions, the Company's share capital by an amount not exceeding 50% of the subscribed and paid-in capital as of the date of this authorization.

Any capital increase or increases that may be agreed upon must be carried out within a maximum period of five (5) years from today's date.

Such capital increase or increases may be carried out, with or without a premium, either by increasing the par value of existing shares in accordance with the requirements set forth in the Law, or by issuing new shares, or through a combination of these methods, with the consideration for the new shares or the increase in the par value of existing shares consisting of cash contributions.

With respect to capital increases carried out under this authorization, the Board of Directors is authorized to exclude, in whole or in part, preemptive subscription rights in accordance with Article 506 of the Capital Companies Act; this authority is limited to capital increases carried out under this authorization and that which is the subject of Item 8 on the agenda, up to a maximum amount corresponding, in total, to 20% of the share capital as of the date of adoption of this resolution. For these purposes, it is hereby noted that, in accordance with the provisions of the thirteenth additional provision of the Capital Companies Act and to the extent that the Company's shares are listed for trading on the BME Growth segment of BME MTF Equity ("BME Growth"), the rules contained in Chapter III of Title XIV of the Capital Companies Act apply to the Company.

The Board of Directors is hereby authorized to request the listing of shares issued by the Company pursuant to this delegation on any official or unofficial, organized or unorganized, domestic or foreign secondary markets, as well as to carry out the procedures and actions necessary or merely advisable for the listing of the shares before the competent authorities of the various domestic or foreign securities markets. Furthermore, the resolution to increase the share capital shall expressly state, for all legal purposes, that, should a request for delisting of the Company's shares be made at a later date, such delisting shall be carried out in accordance with the formalities required by applicable regulations; and, in such a case, the interests of shareholders who oppose or abstain from voting on the resolution shall be safeguarded, in compliance with the requirements established in the Capital Companies Act, Law 6/2023 of March 17 on Securities Markets and Investment Services, and other related or implementing provisions.

As a result of the foregoing resolutions, the Board of Directors is hereby authorized, in all matters not provided for herein, to establish the terms and conditions of share capital increases and the characteristics of the shares, as well as to freely offer any new shares not subscribed for during the period or periods in which the preemptive subscription right may be exercised.

The Board of Directors may also stipulate that, in the event of incomplete subscription, the share capital shall be increased only by the amount of the subscriptions made and may amend the corresponding article of the Bylaws relating to share capital and the number of shares.

The Board of Directors is likewise authorized to delegate the powers conferred by this resolution to any director it deems appropriate, as well as to the non-director Secretary and the non-director Deputy Secretary.

Delegation for the Execution and Formalization of This Resolution

Furthermore, the non-director Secretary and the non-director Deputy Secretary, as well as all members of the Board of Directors, are hereby granted such broad authority as may be necessary under law, so that any of them, without distinction, may take whatever actions are necessary and execute and formalize whatever documents and contracts, whether public or private, are necessary or advisable for the full effectiveness of the foregoing resolutions in any of their aspects and contents and, in particular, to correct, clarify, interpret, complete, specify, and define the resolutions adopted; likewise, to correct any defects, omissions, or errors that may be noted in the verbal or written registration with the Commercial Registry, all of this in the broadest possible terms.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 8.—Delegation to the Board of Directors of the authority to issue fixed-income securities, preferred shares, or instruments of a similar nature (including promissory notes or warrants) convertible into shares of the Company for a maximum amount of 100 million euros over a period of 5 years. Establishment of criteria for determining the terms and conditions of the conversion and granting the Board of Directors the authority to increase capital by the necessary amount, as well as to exclude the preemptive subscription rights of shareholders and holders of convertible securities.

To delegate to the Company's Board of Directors, with express powers of substitution, pursuant to the provisions of Articles 297.1(b), 401, 417, and 511 of the Capital Companies Act and Article 319 of the Commercial Registry Regulations, the authority to issue securities convertible and/or exchangeable into shares, in accordance with the conditions specified below. For these purposes, it is hereby noted that, in accordance with the provisions of the thirteenth additional provision of the Capital Companies Act and to the extent that the Company's shares are listed for trading on the BME Growth segment of BME MTF Equity ("BME Growth"), the rules contained in Chapter III of Title XIV of the Capital Companies Act apply to the Company.

Securities Subject to Issuance: The securities referred to in this delegation may be debentures, bonds, and other fixed-income securities of a similar nature, convertible into newly issued shares of the Company and/or exchangeable for shares of the Company. Likewise, this authorization may be used to issue debentures exchangeable for outstanding shares of another company, to issue warrants or other similar securities that may entitle the holder, directly or indirectly, to subscribe for or acquire shares of the Company or of another company, whether newly issued or already outstanding, settlable through the physical delivery of the shares or, where applicable, by cash settlement, which may be linked or in any way related to each issuance of debentures, bonds, and other simple fixed-income securities of a similar nature carried out under this authorization or to other borrowings or financing instruments through which the Company acknowledges or creates a debt. This authorization may also be used for the issuance of promissory notes or preferred shares.

Term: The issuance of the securities may be carried out in one or more tranches, at any time, within a maximum period of five (5) years from the date of adoption of this resolution.

Maximum Amount: The maximum aggregate amount of the securities issue or issues authorized under this delegation shall be one hundred million euros (100,000,000-€) or its equivalent in another currency.

For the purposes of calculating the foregoing limit, in the case of warrants, the sum of the premiums and exercise prices of the warrants in each issuance approved under this delegation shall be taken into account. In the case of promissory notes, the outstanding balance of the promissory notes issued under the delegation shall be included for the purposes of the foregoing limit.

Scope of the Delegation: In exercising the powers delegated herein, and by way of example only and without limitation, the Board of Directors shall be responsible for determining, for each issuance, its amount—always within the stated overall quantitative limit; the place of issuance (domestic or foreign); the currency; and, if foreign, its equivalent in euros; the type of security, whether bonds or debentures—including subordinated ones—warrants (which may in turn be settled by physical delivery of the shares or, where applicable, by cash settlement), promissory notes, preferred shares, or any other type permitted by law; the issue date or dates; whether the securities are mandatorily or voluntarily convertible and/or exchangeable, including on a contingent basis, and, if voluntarily so, at the option of the security holder or the issuer; when the securities are not convertible, the possibility that they may be exchanged in whole or in part for shares of the issuing Company itself or of another company, or that they may incorporate a right to purchase such shares; the number of securities and their par value, which, in the case of convertible and/or exchangeable securities, shall not be less than the par value of the shares; the interest rate, dates, and procedures for coupon payments; whether the securities are perpetual (including, where applicable, the possibility of redemption by the issuer) or redeemable, and in the latter case, the redemption period and the maturity date; the redemption rate, premiums, and lot sizes, as well as any guarantees; the form of representation, whether by physical certificates or book-entry records; preemptive subscription rights, if any, and the subscription terms; anti-dilution clauses; priority rules and, where applicable, subordination; applicable law; to apply, where applicable, for admission to trading on official or unofficial secondary markets—whether organized or unorganized, domestic or foreign—of the securities to be issued, in accordance with the requirements established in each case by applicable regulations; and, in general, any other terms of the issuance (including subsequent amendments thereto), as well as, where applicable, appointing the trustee and approving the fundamental rules governing the legal relationships between the Company and the syndicate of holders of the securities to be issued, should the formation of such a syndicate be necessary or decided upon. With respect to each specific issuance carried out under this delegation, the Board of Directors may determine all matters not provided for in this resolution. This delegation also grants the Board of Directors the authority to decide, in each case, on the terms of redemption for the securities issued pursuant to this authorization, and to use, to the extent applicable, the redemption methods referred to in Article 430 of the Capital Companies Act or any other applicable methods. Likewise, the Board of Directors is authorized, when it deems it appropriate, and subject to obtaining the necessary official authorizations and, where applicable, the approval of the meetings of the corresponding classes or representative bodies of the security holders, to modify the redemption terms of the issued securities, their respective maturity dates, and the interest rate, if any, accruing on those included in each of the issuances made under this authorization.

Exclusion of Preemptive Subscription Rights: The Board of Directors is expressly delegated, pursuant to Articles 417 and 511 of the Capital Companies Act, the authority to exclude, in whole or in part, the exercise of shareholders' preemptive subscription rights in securities issuances when such exclusion is necessary or in the Company's best interest.

In the event that shareholders' preemptive subscription rights are excluded in the issuance of convertible securities, the Company will only issue convertible securities when the capital increase required for their conversion, added to any capital increases with the exclusion of preemptive subscription rights that may have been approved under the authorization granted by the General Meeting in Resolution No. 7 on the agenda, does not exceed 20% of said total share capital, all in accordance with the terms set forth in the Capital Companies Act.

In any event, if it is decided to exercise the authority to waive preemptive subscription rights, the Board shall prepare the required directors' report. Said report shall be accompanied, if required by applicable regulations, by the corresponding report from an independent expert other than the statutory auditor. The Board of Directors' report shall be made available to the shareholders and presented at the first General Meeting held following the relevant issuance resolution, together with, if applicable, the independent expert's report.

Terms and Conditions of Conversion and/or Exchange: In the event of the issuance of convertible and/or exchangeable bonds, and for the purpose of determining the terms and conditions of such conversion and/or exchange, it is agreed to establish the following criteria:

The securities issued pursuant to this resolution may be convertible into new shares of the Company and/or exchangeable for outstanding shares of the Company itself or of any other company, in accordance with a specified or determinable conversion and/or exchange ratio, with the Board of Directors being authorized to determine whether they are convertible and/or exchangeable, as well as to determine whether they are mandatorily or voluntarily convertible and/or exchangeable, and, if they are voluntarily convertible and/or exchangeable, at the option of the holder or the issuer, with the frequency and during the term established in the issuance agreement, which may not exceed fifteen (15) years from the date of issuance.

The Board of Directors may also establish, in the event that the issue is convertible and exchangeable, that the issuer reserves the right to choose at any time between conversion into new shares or exchange for outstanding shares, with the nature of the shares to be delivered to be specified at the time of conversion or exchange, and may even opt to deliver a combination of newly issued shares and pre-existing shares or an equivalent amount in cash. In any case, the issuer must ensure equal treatment among all holders of fixed-income securities who convert and/or exchange them on the same date.

For the purposes of conversion and/or exchange, the fixed-income securities shall be valued at their par value, and the shares at the exchange ratio determined in the Board of Directors' resolution in which this delegation is exercised, or at the exchange ratio determinable on the date or dates specified in the Board of Directors' resolution itself, and based on the market price of the Company's shares on the date(s) or during the period(s) specified as a reference in said resolution, with or without a premium or discount on said market price. The Board of Directors may determine that the valuation of the shares for the purposes of the conversion and/or exchange may differ for each conversion and/or exchange date. In the case of an exchange for shares of another company,

the same rules shall apply—to the extent required and with any necessary adjustments—though they shall refer to the market price of that company’s shares on the relevant market.

The Board of Directors may establish, in the event that the issue is convertible and exchangeable, that the issuer reserves the right to choose at any time between conversion into new shares or exchange for outstanding shares, with the nature of the shares to be delivered to be specified at the time of conversion or exchange, and the issuer may even choose to deliver a combination of newly issued shares and pre-existing shares. In any case, the issuer must ensure equal treatment among all holders of fixed-income securities that are converted and/or exchanged on the same date.

When conversion and/or exchange occurs, any fractional shares that may be due to the bondholder will be rounded down to the next lower whole number. The Board of Directors shall decide whether to pay each holder the difference in cash that may arise in such a case.

Under no circumstances may the value of the share, for the purposes of the conversion ratio of the bonds into shares, be less than its par value. In accordance with the provisions of Article 415.2 of the Capital Companies Act, bonds may not be converted into shares when the par value of the bonds is less than that of the shares. Nor may convertible bonds be issued for an amount less than their par value.

Upon approving an issuance of convertible bonds pursuant to the authorization granted by the General Shareholders’ Meeting, the Board of Directors shall issue a directors’ report setting forth and specifying, based on the criteria described above, the terms and conditions of conversion specifically applicable to the aforementioned issuance. This report shall be accompanied by the corresponding report from the statutory auditors referred to in Article 414.2 of the Capital Companies Act.

Terms and Conditions for Exercising Warrants: In the case of issuances of warrants convertible and/or exchangeable into shares—to which the provisions of the Capital Companies Act regarding convertible bonds shall apply by analogy—and for the purpose of determining the terms and conditions for their exercise, it is agreed to establish the following criteria:

Warrants issued pursuant to this resolution may entitle the holder to subscribe for new shares issued by the Company or to acquire outstanding shares of the Company or another company, or a combination of either. In any case, the Company may reserve the right to choose, at the time of exercise of the warrant, to deliver new shares, existing shares, or a combination of both, as well as to settle any difference in value.

The term for exercising the warrants shall be determined by the Board of Directors and may not exceed fifteen (15) years from the date of issuance.

The exercise price of the warrants may be fixed or variable depending on the reference date(s) or period(s). Thus, the price will be determined by the Board of Directors at the time of issuance or may be determined at a later date in accordance with the criteria set forth in the resolution itself.

When warrants are issued with simple or par exchange ratios—that is, one share for each warrant—the sum of the premium or premiums paid for each warrant and its exercise price may not, under any circumstances, be less than the par value of the underlying share.

When warrants are issued with multiple exchange ratios—that is, other than one share per warrant—the sum of the premium or premiums paid for all the warrants issued and their aggregate exercise price may not, under any circumstances, be less than the result of multiplying the number of underlying shares corresponding to all the warrants issued by the par value of the underlying share.

At the time of approving an issuance of warrants under this authorization, the Board of Directors shall issue a report setting forth and specifying, based on the criteria described in the preceding sections, the terms and conditions of exercise specifically applicable to the aforementioned issuance. This report shall be accompanied by the corresponding auditors' report provided for in Article 414.2 of the Capital Companies Act.

Rights of Holders of Convertible Securities: To the extent that the conversion and/or exchange into shares of any fixed-income securities that may be issued, or the exercise of warrants, is possible, their holders shall have all the rights granted to them under applicable law and, in particular, where applicable, those relating to the preemptive subscription right (in the case of convertible bonds or warrants on newly issued shares) and the anti-dilution clause in the cases provided for by law, without prejudice to the provisions of subsection (ix)a below.

Capital Increase and Exclusion of Preemptive Rights in Convertible Securities: The delegation of authority to the Board of Directors also includes, by way of example and without limitation, the following powers:

The authority for the Board of Directors, pursuant to the provisions of Articles 308, 417, and 511 of the Capital Companies Act, to exclude, in whole or in part, the preemptive subscription rights of shareholders and holders of convertible bonds and, where applicable, warrants on newly issued shares, when, in the context of a specific issuance of convertible bonds or warrants on newly issued shares, this is required to raise financial resources in international markets, to employ demand-sounding techniques, to bring in industrial or financial investors who may facilitate value creation and the achievement of the Company's strategic objectives, or is otherwise justified by the Company's interests.

In such a case, the maximum number of shares into which the bonds may be converted, based on their initial conversion ratio (if fixed) or their minimum conversion ratio (if variable), plus the number of shares issued by the directors pursuant to the delegation provided for in Article 506 of the Capital Companies Act, shall not

exceed twenty percent of the number of shares comprising the share capital at the time of this authorization.

In any event, if the Board of Directors decides to waive the preemptive subscription right in connection with a specific issuance of convertible bonds or warrants that it may decide to carry out under this authorization, it shall issue, at the time of approving the issuance and in accordance with applicable regulations, a report detailing the specific reasons of corporate interest justifying such measure, which shall be accompanied, if required, the corresponding report from the statutory auditor referred to in Articles 417.2 and 511.3 of the Capital Companies Act. Such reports shall be made available to shareholders and holders of convertible bonds and warrants on newly issued shares and communicated to the first General Meeting held following the resolution authorizing the issuance.

The authority to increase capital by the amount necessary to meet requests for conversion or the exercise of warrants on newly issued shares. This authority may only be exercised to the extent that the Board of Directors, when adding the capital to be increased to cover the issuance of convertible bonds or the exercise of warrants to the remaining capital increases it has previously approved under authorizations granted by the General Shareholders' Meeting, does not exceed the limit of one-half of the current share capital provided for in Article 297.1(b) of the Capital Companies Act, nor 20% of said total share capital in the event that shareholders' preemptive subscription rights are excluded in the issuance of convertible securities. This authorization to increase capital includes the authority to issue and put into circulation, in one or more installments, the shares representing said capital that are necessary to effect the conversion or the exercise of the warrant, as well as the authority to amend the article of the bylaws relating to the amount of capital and, where applicable, to cancel the portion of said capital increase that was not necessary for the conversion into shares or for the exercise of the warrant.

The authority to develop and specify the terms and conditions of the conversion and/or exchange, taking into account the criteria set forth in sections (vi) and (vii) above, including, among other matters, setting the timing of the conversion and/or exchange or exercise of the warrants and, in general and in the broadest terms, determining all matters and conditions deemed necessary or appropriate for the issuance.

Listing: The Company shall, where appropriate, apply for the listing of debentures, bonds, preferred shares, warrants, and any other securities issued pursuant to this delegation, authorizing the Board of Directors to carry out the necessary procedures and actions for listing with the competent authorities of the various domestic or foreign securities markets.

Substitution: The Board of Directors is authorized to delegate to any of the directors the powers conferred pursuant to this resolution that are delegable.

Delegation of Powers: Furthermore, the Board authorizes the non-director Secretary and the non-director Deputy Secretary, as well as

all members of the Board of Directors, so that any of them, without distinction, may take whatever actions are necessary and execute and formalize whatever documents and contracts, whether public or private, may be necessary or appropriate for the full effectiveness of the foregoing resolutions in all their aspects and contents and, in particular, to correct, clarify, interpret, complete, specify, and define the resolutions adopted; likewise, to correct any defects, omissions, or errors that may be noted in the verbal or written registration with the Commercial Registry, all of this in the broadest possible terms.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 9.—Authorization for the Board of Directors to acquire the Company’s own shares, either directly or, where applicable, through subsidiaries of the Company, for a period of 5 years

It is unanimously resolved to authorize the Board of Directors to acquire the Company’s own shares, either directly or, where applicable, through its subsidiaries, subject to the following limits and requirements:

- a) Methods of acquisition: acquisition by means of a purchase agreement, by any other “inter vivos” transaction for valuable consideration, or by any other method permitted by law.
- b) Maximum number of shares to be acquired: Acquisitions may be made, at any given time, up to the maximum number permitted by law.
- c) Minimum and maximum purchase price: The minimum purchase price of the shares shall be one euro cent, and the maximum price shall be equal to 120% of their market value on the date of acquisition.
- d) Term of the authorization: five (5) years from the date of this resolution.

It is unanimously approved to authorize the Board of Directors to allocate, in whole or in part, the acquired treasury shares to the implementation of compensation programs whose purpose is or involves the grant of shares or stock options, in accordance with the provisions of Article 146(1)(a) of the Capital Companies Act.

Based on the foregoing, it is agreed to empower the Board of Directors, in the broadest terms, to use the authorization that is the subject of this resolution and to fully implement and carry it out, with the Board of Directors being authorized to delegate these powers to any person whom it expressly authorizes for this purpose, to the extent it deems appropriate.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%

Item 10.—Delegation of powers to the Company’s Board of Directors, with express authority to substitute and subdelegate, for the formalization, interpretation, rectification, and/or execution of the resolutions adopted by the General Meeting

To expressly authorize each and every Director, and the Secretary who is not a member of the Board of Directors, Mr. Miquel Pujolriu Giménez, as well as any other persons with sufficient authority to do so, so that any of them, acting jointly and severally, may execute and appear before a notary public to formalize the foregoing resolutions, executing as many public and private documents as necessary—including those for rectification, ratification, or correction—and taking whatever actions are required until their complete registration or filing, as applicable, with the Commercial Registry, with the express authority to delegate further and subdelegate.

- Votes in favor: 100%
- Votes against: 0%
- Abstentions: 0%